High performance of the DNA methylation-based WID-qEC test for detecting uterine cancers independent of sampling modalities.
DNA methylation
collection modalities
early detection
endometrial cancer
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
13 May 2024
13 May 2024
Historique:
revised:
11
04
2024
received:
09
02
2024
accepted:
16
04
2024
medline:
13
5
2024
pubmed:
13
5
2024
entrez:
13
5
2024
Statut:
aheadofprint
Résumé
Endometrial cancer (EC) is the most prevalent gynaecological cancer in high-income countries and its incidence is continuing to rise sharply. Simple and objective tools to reliably detect women with EC are urgently needed. We recently developed and validated the DNA methylation (DNAme)-based women's cancer risk identification-quantitative polymerase chain reaction test for endometrial cancer (WID-qEC) test that could address this need. Here, we demonstrate that the stability of the WID-qEC test remains consistent regardless of: (i) the cervicovaginal collection device and sample media used (Cervex brush and PreservCyt or FLOQSwab and eNAT), (ii) the collector of the specimen (gynaecologist- or patient-based), and (iii) the precise sampling site (cervical, cervicovaginal and vaginal). Furthermore, we demonstrate sample stability in eNAT medium for 7 days at room temperature, greatly facilitating the implementation of the test into diagnostic laboratory workflows. When applying FLOQSwabs (Copan) in combination with the eNAT (Copan) sample collection media, the sensitivity and specificity of the WID-qEC test to detect uterine (i.e., endometrial and cervical) cancers in gynaecologist-taken samples was 92.9% (95% confidence interval [CI] = 75.0%-98.8%) and 98.6% (95% CI = 91.7%-99.9%), respectively, whilst the sensitivity and specificity in patient collected self-samples was 75.0% (95% CI = 47.4%-91.7%) and 100.0% (95% CI = 93.9%-100.0%), respectively. Taken together these data confirm the robustness and clinical potential of the WID-qEC test.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : H2020 European Research Council
ID : 742432
Organisme : The Eve Appeal
Organisme : Land Tirol
Informations de copyright
© 2024 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913‐2921.
Lortet‐Tieulent J, Ferlay J, Bray F, Jemal A. International patterns and trends in endometrial cancer incidence, 1978‐2013. J Natl Cancer Inst. 2018;110:354‐361.
Clarke MA, Devesa SS, Harvey SV, Wentzensen N. Hysterectomy‐corrected uterine corpus cancer incidence trends and differences in relative survival reveal racial disparities and rising rates of nonendometrioid cancers. J Clin Oncol. 2019;37:1895‐1908.
Clarke MA, Devesa SS, Hammer A, Wentzensen N. Racial and ethnic differences in hysterectomy‐corrected uterine corpus cancer mortality by stage and histologic subtype. JAMA Oncol. 2022;8:895‐903.
Sud A, Torr B, Jones ME, et al. Effect of delays in the 2‐week‐wait cancer referral pathway during the COVID‐19 pandemic on cancer survival in the UK: a modelling study. Lancet Oncol. 2020;21:1035‐1044.
Pennant ME, Mehta R, Moody P, et al. Premenopausal abnormal uterine bleeding and risk of endometrial cancer. BJOG. 2017;124:404‐411.
Evans I, Reisel D, Jones A, et al. Performance of the WID‐qEC test versus sonography to detect uterine cancers in women with abnormal uterine bleeding (EPI‐SURE): a prospective, consecutive observational cohort study in the UK. Lancet Oncol. 2023;24:1375‐1386.
Emons G, Steiner E, Vordermark D, et al. Endometrial cancer. Guideline of the DGGG, DKG and DKH (S3‐level, AWMF registry number 032/034‐OL, September 2022). Part 1 with recommendations on the epidemiology, screening, diagnosis and hereditary factors of endometrial cancer, geriatric assessment and supply structures. Geburtshilfe Frauenheilkd. 2023;83:919‐962.
Colombo N, Preti E, Landoni F, et al. Endometrial cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow‐up. Ann Oncol. 2013;24(Suppl 6):vi33‐vi38.
Long B, Clarke MA, Morillo ADM, Wentzensen N, Bakkum‐Gamez JN. Ultrasound detection of endometrial cancer in women with postmenopausal bleeding: systematic review and meta‐analysis. Gynecol Oncol. 2020;157:624‐633.
Frias‐Gomez J, Benavente Y, Ponce J, et al. Sensitivity of cervico‐vaginal cytology in endometrial carcinoma: a systematic review and meta‐analysis. Cancer Cytopathol. 2020;128:792‐802.
Wang J, Edvardsson H, Strander B, Andrae B, Sparen P, Dillner J. Long‐term follow‐up of cervical cancer incidence after normal cytological findings. Int J Cancer. 2024;154:448‐453.
Herzog C, Marin F, Jones A, et al. A simple cervicovaginal epigenetic test for screening and rapid triage of women with suspected endometrial cancer: validation in several cohort and case/control sets. J Clin Oncol. 2022;40:3828‐3838.
Schreiberhuber L, Herzog C, Vavourakis CD, et al. The WID‐qEC test: performance in a hospital‐based cohort and feasibility to detect endometrial and cervical cancers. Int J Cancer. 2023;152:1269‐1274.
Bland DGAJM. Measurement in medicine: the analysis of method comparison studies. J R Stat Soc Series B Stat. 1983;32(3):307‐317.
Elfstrom M, Gray PG, Dillner J. Cervical cancer screening improvements with self‐sampling during the COVID‐19 pandemic. Elife. 2023;12:e80905.
Waisel DB. Vulnerable populations in healthcare. Curr Opin Anaesthesiol. 2013;26:186‐192.
Crispens MA. Endometrial and ovarian cancer in lynch syndrome. Clin Colon Rectal Surg. 2012;25:97‐102.